Novartis' Gilenia Extension Trial Data Support Efficacy Of Low-Dose Version
This article was originally published in The Pink Sheet Daily
Executive Summary
Two-year data on the oral multiple sclerosis drug show sustained efficacy, and potential benefits of switching from interferon-1a, Novartis says.
You may also be interested in...
Innate Therapeutics Wins $550K From Fast Forward For Therapy Aimed At Progressive MS
Validation from the venture philanthropy garnered the New Zealand biotech another NZD600,000 from the NZ government.
Innate Therapeutics Wins $550K From Fast Forward For Therapy Aimed At Progressive MS
Validation from the venture philanthropy garnered the New Zealand biotech another NZD600,000 from the NZ government.
Novartis Revamps U.S. Pharma Unit, With New CEO Andre Wyss
Novartis is reorganizing its U.S. pharmaceutical business, effective May 1, a move that includes the departure of Ludwig Hanston, who ran the unit for the past two years, and the elimination of nearly 400 positions mostly at U.S. headquarters, the company's Global Pharma CEO David Epstein told employees in a memo distributed on April 13